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A novel mouse macrophage galactose-type C-type lec-
tin 2 (mMGL2) was identified by BLAST analysis of ex-
pressed sequence tags. The sequence of mMGL2 is
highly homologous to the mMGL, which should now be
called mMGL1. The open reading frame of mMGL2 con-
tains a sequence corresponding to a type II transmem-
brane protein with 332 amino acids having a single ex-
tracellular C-type lectin domain. The 3-untranslated
region included long terminal repeats of mouse early
transposon. The Mgl2 gene was cloned from a 129/SvJ
mouse genomic library and sequenced. The gene spans
7,136 base pairs and consists of 10 exons, which is simi-
lar to the genomic organization of mMGL1. The reverse
transcriptase-PCR analysis indicates that mMGL2 is ex-
pressed in cell lines and normal mouse tissues in a mac-
rophage-restricted manner, also very similar to that of
mMGL1. The mMGL2 mRNA was also detected in
mMGL1-positive cells, which were sorted from thiogly-
collate-induced peritoneal cells with a mMGL1-specific
monoclonal antibody, LOM-8.7. The soluble recombi-
nant proteins of mMGL2 exhibited carbohydrate speci-
ficity for - and -GalNAc-conjugated soluble polyacryl-
amides, whereas mMGL1 preferentially bound Lewis
X-conjugated soluble polyacrylamides in solid phase as-
says. These two lectins may function cooperatively as
recognition and endocytic molecules on macrophages
and related cells.
Macrophages (MØs)1 and related cells are widely distributed
throughout the body, displaying a morphological and func-
tional diversity. They are found in the lymphoid organs, liver,
lungs, gastrointestinal tract, central nervous system, serous
cavities, bones, synovia, and skin. Resident MØs mediate clear-
ance of senescent or apoptotic cells, produce and secrete cyto-
kines, are involved in hemopoiesis and bone resorption, trans-
port and present antigens, and regulate neuroendocrine
processes. Activated MØs are recruited to sites of infection,
tissue injury, inflammation, and neoplasia and play crucial
roles in tissue repair and pathogenesis (1).
The distribution and functional heterogeneity of MØs derive
in part from their specialized plasma membrane receptors (2).
Cell surface markers such as F4/80, sialoadhesin, MØ mannose
receptor and scavenger receptor type A have significantly con-
tributed to the current understanding of MØ ontogeny and
function (3). However, in comparison to other immune cells
such as B and T lymphocytes, relatively few MØ-restricted cell
surface molecules have been identified. The physiological and
pathological roles of these putative markers remain unknown.
Protein-carbohydrate interactions serve a variety of func-
tions in the immune system. A number of lectins (carbohy-
drate-binding proteins) mediate both pathogen recognition and
cell-to-cell interactions using structurally related carbohydrate
recognition domains (CRDs). One of the most diversified fam-
ilies of these CRDs is Ca2-dependent and termed C-type CRDs
(4, 5). MØs and related cells such as dendritic cells are known
to express several subfamilies of C-type lectins: type 1 multi-
lectins such as MØ mannose receptor and lectins having type II
transmembrane configurations such as MØ galactose-type
(known previously as galactose/N-acetylgalactosamine-spe-
cific) C-type lectin (MGL). These lectins seem to mediate car-
bohydrate-specific endocytosis (6–11). Little is known regard-
ing the expression of selectins, another subfamily of C-type
lectins, in MØs and related cells.
Previously, MGL was cloned from rats, mice, and humans
and characterized. The lectin from mice was shown to have
specific affinity for highly branched N-linked carbohydrate
chains with terminal -galactosyl groups and glycopeptides
carrying three consecutive -GalNAc-Ser/Thr (Tn-antigens)
(12). A human MGL was also shown to have affinity for glyco-
peptides carrying three consecutive Tn-antigens (13). Surface
* This work was supported by grants-in-aid from the Ministry
of Education, Science, Sports and Culture of Japan (09254101,
11557180, 11672162, and 12307054), from the Research Association for
Biotechnology, Special Coordination Funds for Promoting Science and
Technology of the Ministry of Education, Culture, Sports, Science
and Technology, and from the Program for Promotion of Basic
Research Activities for Innovative Biosciences. The costs of publication
of this article were defrayed in part by the payment of page charges.
This article must therefore be hereby marked “advertisement” in ac-
cordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted
to the DDBJ/GenBankTM/EBI Data Bank with accession number(s)
AY103461, AY103462.
‡ Present address: Dept. of Applied Biological Chemistry, Graduate
School of Agricultural and Life Sciences, The University of Tokyo,
Tokyo, 113-8657, Japan.
¶ To whom correspondence should be addressed. Tel.: 813-5841-4870;
Fax: 813-5841-4879; E-mail: irimura@mol.f.u-tokyo.ac.jp.
1 The abbreviations used are: MØ, macrophage; ABTS, 2,2-amino-
bis(3-ethylbenzthiazoline-6-sulfonic acid); ASGR, hepatic asialoglyco-
protein receptor; BAC, bacterial artificial chromosome; BSA, bovine
serum albumin; CRD, carbohydrate-recognition domain; DPBS, Dulbec-
co’s phosphate-buffered saline; HRP, horseradish peroxidase; MGL,
macrophage galactose-type C-type lectin; RHL, rat hepatic lectin; RT,
reverse transcriptase; TG-PEC, thioglycollate-induced peritoneal cells;
RACE, rapid amplification of cDNA ends; STAT, signal transducers and
activators of transcription; mAb, monoclonal antibody; MES, 4-morpho-
lineethanesulfonic acid; MOPS, 4-morpholinepropanesulfonic acid; h,
human; m, mouse; r, rat.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 277, No. 32, Issue of August 9, pp. 28892–28901, 2002
© 2002 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org28892
 at U
niversity of T










plasmon resonance revealed that affinity of recombinant
hMGL for immobilized glycopeptides increased in parallel with
the number of GalNAc residues (14). Tn-antigen was known as
a marker of malignant cells, and MGL was shown to play a role
as a recognition molecule on MØs for tumor cells (15–17).
Immunohistochemical localization of mouse MGL (mMGL)
with specific monoclonal antibodies revealed that this lectin
has a strong association with MØs residing in connective tissue
and those infiltrated into tumor tissues (18–20). Recent studies
demonstrated that this lectin is also expressed on the surface of
immature dendritic cells and is involved in the uptake of gly-
cosylated antigens in mice and humans (21, 22).
A C-type lectin highly homologous to MGL and expressed
mainly on hepatocytes, the hepatic asialoglycoprotein receptor
(ASGR), has two isomers in mice, rats, and humans, apparently
due to recent gene duplication. Previously, MGL was believed
to have a single gene. Southern blotting analysis supported this
notion. However, in this report, we describe the properties of
another novel MØ galactose-type C-type lectin, mMGL2. As an
obvious consequence, the previous mMGL must now be called
mMGL1. These lectins are highly homologous to each other
except in their cytoplasmic domains and CRDs. We found that
mMGL2 has a distinct carbohydrate specificity from mMGL1.
These lectins seem to be expressed on the same cells and
therefore seem to function cooperatively.
EXPERIMENTAL PROCEDURES
Cells—The following cell lines were provided by Cell Resource Center
for Biomedical Research, Institute of Development, Aging and Cancer
Tohoku University, Sendai, Japan: L929, JLS-V9, EL4, RL1, YAC-1,
BCL1-B20, P815, P388, and M1 cells. RAW264.7 cells were purchased
from ATCC. All cells were cultured in RPMI 1640 media with 10% fetal
calf serum at 37 °C with 5% CO2.
Thioglycollate-induced peritoneal cells (TG-PEC) were obtained from
6–8-week old female C57BL/6J mice from Clea Japan, Inc (Kawasaki,
Japan). These were maintained under pathogen-free conditions. These
mice received 1 ml of 4% thioglycollate broth (Difco, Detroit, MI) by
intraperitoneal injection. Four days later, mice were sacrificed by neck
dislocation, and peritoneal exudate cells were harvested by lavage with
5 ml of RPMI 1640 media on ice.
TG-PEC were suspended in chilled 0.1% BSA/Dulbecco’s modified
phosphate-buffered saline (DPBS: 137 mM NaCl, 13.4 mM KCl, 40.5 mM
Na2HPO4, 7.35 mM KH2PO4, 0.49 mM MgCl2, 0.905 mM CaCl2) contain-
ing phycoerythrin-labeled mAb LOM-14 (reactive with mMGL1 and
mMGL2 as described below) and biotin-labeled mAb LOM-8.7 (reactive
with mMGL1) and then incubated with streptavidin-fluorescein isothio-
cyanate (Zymed Laboratories Inc., South San Francisco, CA) on ice. The
cells were sorted for the expression of mMGL1 (mAb LOM-8.7 staining)
by Epics Elite (Beckman Coulter).
Mice—Mgl1/ mice were prepared in Hedrick’s laboratory at the
University of California, San Diego, CA. The details will be published in
a separate study (23).
RNA Preparations and RT-PCR Analysis—Total RNAs were ex-
tracted by using Ultraspec RNA zol (Biotecx, Houston, TX) according to
the manufacturer’s instructions. First-strand cDNA synthesis was car-
ried out using oligo(dT)12–18 and Superscript II (Invitrogen). The cDNA
was used as the template in PCR reactions using Ampli Taq Gold
polymerase (Applied Biosystems). PCR was performed with specific




GCCATGAGGTCCACCAC-3). The specific primers were designed with
Genetyx-Mac (Software Development Co. Ltd., Tokyo, Japan). The con-
ditions were 94 °C for 30 s, 65 °C for 30 s, and 72 °C for 2 min for 40
cycles. Amplifications of G3pdh were used as a control for cDNA quan-
tity. The conditions were 94 °C for 30 s, 61 °C for 30 s, and 72 °C for 1
min for 25 cycles. The PCR products were then separated on 1% agarose
gels, stained with ethidium bromide, and visualized with the Fluor-S
image analyzer (Bio-Rad).
Rapid Amplification of cDNA Ends (RACE)—The poly(A) RNA from
RAW264.7 cells were isolated using a MACS mRNA isolation kit
(Miltenyi Biotec). Adapter-ligated cDNA were synthesized using the
Marathon cDNA amplification kit (CLONTECH). To obtain a full-
length cDNA of mMGL2, an antisense primer, AS3 (5-TCCTCCA-
CATCCACTTTCAGAG-3), and a sense primer, 3S1 (5-TTGGAGCGG-
GAAGAGAAAAACCAG-3), were designed from the expressed
sequence tag clones for 5-RACE and 3-RACE reactions, respectively.
Reactions were incubated at 95 °C for 10 min followed by 43 cycles at
94 °C for 45 s, 60 °C for 45 s, and 72 °C for 2 min. The resulting 1.5-kbp
and 700-bp products were subcloned into the pGEM-T easy vector
(Promega UK, Southampton, UK) and sequenced with the dye primer
method.
Screening of the Genomic Clone Coded the mMgl2 Gene—A 129/SvJ
mouse genomic library (Stratagene; vector FIXII) was screened with
the complete mMGL1 cDNA coding sequence labeled by random prim-
ing with 32P by plaque hybridization. The fragments of positive clones
were subcloned into pBluescript SK() (Stratagene). These clones were
sequenced with 24 specific primers with the dye-terminator method.
These sequences were assembled and aligned using Genetyx-Mac.
Production and Isolation of Soluble mMGL2—cDNA encoding
mMGL1 and mMGL2 was cloned into pGEM-T easy vector (Promega).
The vector was digested with BamHI and SacI (for mMGL1) or BamHI
and NotI (for mMGL2). The fragments encoding these neck and CRD
domains were separated with agarose gel electrophoresis and inserted
into each site of expression plasmid vector pET-21a (Novagen). The
BL21(DE3) cells containing the plasmid were grown to mid-log phase at
37 °C in 2 TY medium (1.2 liters) and then treated with isopropyl
-D-thiogalactoside at a concentration of 1 mM. After isopropyl -D-
thiogalactopyranoside induction, the cultured cells were washed with
50 mM Tris-HCl, pH 8.0, containing 0.15 M NaCl (TBS) and suspended
in TBS containing phenylmethanesulfonyl fluoride. The cell lysates
were prepared by freezing and thawing, and after the addition of DNase
I (final 50 units/ml) and lysozyme (final 0.2 mg/ml), they were incubated
1 h at 37 °C and then centrifuged at 15,000  g for 10 min at 4 °C.
Expressed proteins formed inclusion bodies. The pellets were washed
with TBS containing 0.5% Triton X-100 and 10 mM EDTA and then with
H2O. The washed pellets were solubilized with 2 M NH4OH (20 ml) and
then added to 25 mM MOPS buffer, pH 7.0, containing 2 mM glutathi-
one, reduced form, 0.2 mM glutathione, oxidized form, 20 mM CaCl2, 0.5
M NaCl, and 0.02% NaN3 (20 ml). These solutions were then dialyzed
against 25 mM MOPS buffer, pH 7.0, containing 20 mM CaCl2, 0.5 M
NaCl, and 0.02% NaN3. Soluble recombinant mMGL1 and mMGL2
were purified by affinity chromatography on a column of galactose-
Sepharose 4B, as described previously (24).
Solid Phase Binding Assays—Absorption of the purified soluble re-
combinant mMGL1 or mMGL2 onto enzyme-linked immunosorbent
assay plates (655061, Greiner) was carried out by adding 100 l of
solution (3 g/ml in DPBS) to each well and incubating the plates for
18 h at 4 °C. After blocking of the wells using 3% bovine serum albumin
(BSA) in DPBS for 2 h at room temperature, 150 l solution of biotiny-
lated soluble polyacrylamide with attached mono- or oligosaccharides
(GlycoTech, Rockville, MD) or hybridoma culture supernatant, diluted
into varying concentrations with DPBS containing 3% BSA, were added
to each well. After incubation for 2 h at 4 °C (at room temperature for
mAb reactions), the wells were washed three times with DPBS to
remove unbound materials, and then 100 l of HRP-conjugated strepta-
vidin solution (1.25 g/ml in DPBS) or HRP-conjugated goat anti-rat
IgG (H  L) solution (0.375 g/ml in DPBS) for rat mAbs was added to
detect bound materials. After incubation for 1 h at room temperature,
the wells were washed three times with DPBS. Subsequently, 100 l of
1 mM 2, 2-amino-bis(3-ethylbenzthiazoline-6-sulfonic acid) ammonium
(ABTS) solution containing 0.34% H2O2 in 0.1 M sodium citrate buffer
(pH 4.3) was added, and the absorbance was measured at 405 nm on a
microplate reader (25).
To determine pH dependence of the binding of mMGL1 and mMGL2,
the incubation conditions were modified as follows. After the blocking
buffer was removed, the wells were washed three times with DPBS.
Aliquots (50 l) of biotinylated soluble polyacrylamide in 2 incubation
buffer (274 mM NaCl, 26.8 mM KCl, 0.98 mM MgCl2, 1.810 mM CaCl2, 2%
BSA) were mixed with equal volumes of 2 pH buffer (50 mM sodium
acetate buffer at pH 4.5–6.0, 50 mM MES buffer at pH 6.0–7.0, 50 mM
Tris-HCl buffer at pH 7.0–8.0) and transferred to each well. Incubation
was performed at 4 °C for 1.5 h. The wells were emptied and washed
three times with DPBST (DPBS containing 0.1% Tween 20) and 100 l
of HRP-conjugated streptavidin solution (Zymed Laboratories Inc.,
1000  in DPBS containing 1% BSA) was added and incubated for 1 h
at 4 °C. The wells were emptied and washed three times with DPBST,
and then 100 l of ABTS solution containing 0.034% H2O2 (1 mM ABTS
dissolved in 0.1 M sodium citrate buffer, pH 4.2) was added, and ab-
sorbance at 405 nm was determined.
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FIG. 1. The nucleotide sequence of the mMGL2 cDNA. A, the nucleotide sequence of the mMGL2 cDNA and its deduced amino acid
sequence. The putative transmembrane domain is underlined. The poly-A addition signal is underlined with a broken line. The potential
N-glycosylation site is underlined with a wavy line. The putative internalization signal is boxed. B, amino acid sequences of mMGL1 and mMGL2.














Immunohistochemical Staining—MGL-positive cells were immuno-
histochemically detected in the skin as described previously (19). In
brief, skin samples freshly prepared from Mgl1/ mice and their lit-
termates were embedded in OCT compound (Miles, Elkhart, IN) and
frozen in a liquid nitrogen bath. Cryostat sections (10 m thick) were
picked up on poly-L-lysine-coated slides and fixed in ice-cold acetone for
10 min. Nonspecific bindings were blocked using a blocking solution (2%
normal mouse serum and 3% BSA in DPBS) for 10 min. The sections
were treated with the first antibodies for 1 h and then treated with
biotinylated mAb mouse anti-rat  and  (1⁄50 dilution) for 30 min and
finally treated with alkaline phosphatase-streptavidin (1⁄100 dilution)
for 30 min. The staining was visualized using Histomark Red, and the
cell nucleus was counterstained in Mayer’s hematoxylin after post-
fixation using 2% glutaraldehyde in DPBS. The sections were observed
under a light microscope (TMD-300, Nikon, Tokyo, Japan).
RESULTS
Cloning of a Novel Macrophage C-type Lectin—We found four
clones (GenBankTM accession numbers AA511511, AA537107,
AA671707, and AA498512) similar to mMGL (mMGL1, Gen-
BankTM accession number S36676) and hMGL (HML-2, Gen-
BankTM accession number D50532) in the data base of mouse
expressed sequence tag. To obtain the full sequences of a novel
C-type lectin, 5- and 3-RACE reactions were performed using
mRNA from RAW264.7 cells as a template and with specific
primers designed to match these expressed sequence tag
clones. The full-length cDNA was prepared by RT-PCR of
poly(A) RNA from RAW264.7 cells. The obtained full-length
cDNA (GenBankTM accession number AY103461) encodes an
open reading frame of 996 base pairs, predicting a protein of
332 amino acid residues (38,067 Da), which we subsequently
termed mMGL2 (Fig. 1). The 3-untranscription region has a
sequence of long terminal repeat (LTR) of mouse early trans-
poson (26, 27). The nucleotide sequence of mMGL2 has 79.0
and 54.9% identity with that of mMGL1 and hMGL (HML-2),
respectively. The amino acid sequence of mMGL2 has 91.5 and
51.8% identity with that of mMGL1 and hMGL (HML-2), re-
spectively. The neck domain is highly homologous to mMGL1
at 95.3%. Only five residues (Ile-87, Asn-108, Leu-144, Glu-166,
and Thr-167) were different in the neck domain from Arg-78 to
Gly-183. Amino acids within the CRD (corresponding to exons
8–10), particularly those corresponding to the last exon (exon
10), showed differences between mMGL1 and mMGL2. In the
sequence of cytoplasmic domain (corresponding to exon 2),
mMGL2 has a putative internalization signal (YXX) (28),
which is also present in mMGL1, and an insertion of extra 14
amino acid residues. A consensus sequence for polyadenylation
signal is present in nucleotides 1467–1472 followed by a
poly(A) tail. There are two potential N-glycosylation sites (Fig.
1), both in mMGL1 and -2.
Genomic Structure and Chromosome Location of mMGL2—
Screening of a 129/SvJ mouse genomic library led to the isola-
tion of three clones. Two clones (termed 92b and 41b) were
FIG. 2. Genomic structure of Mgl2
gene. As shown in A, the gene spans 7136
bp and consists of 10 exons and is a sim-
ilar to Mgl1 in genomic organization. The
untranslated regions are shown as closed
boxes, and the coding regions are shown
as hatched boxes. The initiation codon is
within the second exon. B, the linkage of
BAC clones. We identified the BAC clone
RPCI-23–172M21, which encodes the
Mgl2, Asgr1, and Asgr2 genes. RPCI-23–
198E14 encodes Mgl2 and Mgl1. C, the
promoter sequences of Mgl2 gene. Tran-
scription factor binding site consensus se-
quences were searched using the tran-
scription factor data base (www.cbrc.jp/
research/db/TFSEARCH.html).
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included in the Mgl (Mgl1) gene (GenBankTM accession num-
ber AF132744) (29), but the other clone (termed 41a) was
included in the Mgl2 gene, confirmed by PCR using primers of
mMGL2. The latter gene spans 7136 bp, consists of 10 exons,
and is similar to Mgl (Mgl1) in genomic organization (Fig. 2A).
The GenBankTM accession number of the Mgl2 gene is
AY103462. The intron/exon boundaries were defined using
DNA sequencing. All splice sites conform to the AG/GT rule
(Table I). This clone contains 5-upstream sequences. To iden-
tify the promoter sequences of the Mgl2 gene, transcription
factor binding site consensus sequences were searched using
the transcription factor data base (www.cbrc.jp/research/db/
TFSEARCH.html). The promoter lacks a classical TATA box
but contains several binding sites for other transcription fac-
tors, C/EBP, CF1/, AML-1, c-Ets, PU.1, c-Rel, Oct-1, Lyf-1,
AP-1, GATAs, and STATs. These features are almost identical
to that of the 5-flanking motifs of the Mgl1 gene. These are the
sites found upstream of genes expressed preferentially by cells
of monocyte/MØ lineages (Fig. 2C).
We identified the BAC clone RPCI-23–172M21, which coded
the Mgl2, Asgr1, and Asgr2 genes. The other clone RPCI-23–
198E14 encodes the Mgl2 and Mgl1 genes. These BAC clones
have been constructed from the genomic DNA of female
C57BL/6J mice. Therefore, these four C-type lectin genes
should be located within about 150 kb on mouse chromosome
11 (Fig. 2B).
Reactivity with Monoclonal Antibodies—Previously, we have
obtained mAbs specific for MGL1 using purified mMGL (likely
to be a mixture of mMGL1 and mMGL2) and recombinant
MGL1 as immunogens. Screening to obtain specific monoclonal
antibodies was performed previously with recombinant
mMGL1 (25). The antibodies are mAb LOM-4.7, mAb LOM-8.2,
mAb LOM-8.7, all shown to have blocking activity, mAb LOM-
11, shown to recognize the ligand-induced binding site, and a
non-blocking mAb LOM-14 (25, 30). As shown in Fig. 3, mAb
LOM-4.7, mAb LOM-8.2, mAb LOM-8.7, and mAb LOM-11
were shown to be specific for MGL1. LOM-14 bound to both
MGL1 and MGL2 (Fig. 3). These results suggested that the
most diverse region of these lectins was the ligand binding site.
Distribution of mMGL2 mRNA in Tissue and Cells—As a
means of testing the expression profiles of this putative gene
and mMgl1, RT-PCR analysis was performed on 10 mouse
cell lines including L929 (fibroblast line), JLS-V9 (fibroblast-
like bone marrow-derived cell line), EL4 (thymoma cell line),
RL1 (lymphoma cell line), YAC-1 (lymphoma cell line),
BCL1-B20 (malignant B cells), P815 (mastocytoma cells),
P388 (MØ-like lymphoid cell line), M1 (myeloblastic leuke-
mia cells), and RAW264.7 (MØ-like cell line). The 644-bp
bands indicating mMgl2 were found only in the cell lines
P388 and RAW264.7 (Fig. 4A). These cell lines were also high
expressers of mMgl1. To assess the expression patterns of
mMgl1 and mMgl2 in vivo, RT-PCR analysis was conducted
FIG. 3. Binding of mAbs to the recombinant mMGL1 and
mMGL2. The binding of mAbs LOM-4.7, LOM-8.2, LOM-8.7, LOM-11,
and LOM-14 to the immobilized recombinant mMGL1 (A) and mMGL2
(B) was measured according to mAb concentration. The binding of mAbs
was detected using HRP-conjugated goat mAbs specific for rat IgG (H 
L). Absorbance at 405 nm was measured on a microplate reader. The
values represent means of triplicate determinations, and the error bars
indicate S.D.
TABLE I
Splice junction sequences, exon sizes, and estimated intron sizes of the mouse Mgl2 gene
Exon sequences are in capital letters; intron sequences are in lowercase letters.





sequence Intron size Intron phase
bp bp
1 1–23 23 CACAGgtaac 3684
2 24–168 145 ttcagTTCTG TCTAAgtatg 787 1
3 169–279 111 agcagTTCCT CCAAAgtggg 428 1
4 280–375 96 atcagATTCC CAGGGgtgag 83 1
5 376–447 72 tgcagCTGAC GGCAGgtgag 79 1
6 448–519 72 ttcagGCCGA AACAGgtgag 258 1
7 520–606 87 cccagATCTG CAATGgtgag 103 1
8 607–758 152 cgtagGCTCG AGCAGgtgat 77 0
9 759–865 107 tttagAATTT TTCAAgtacg 144 2
10 866–1530 629 ttcagGAATT














FIG. 4. RT-PCR analysis of mMGL1 and mMGL2 mRNA expression in cells and tissue. A, the cDNA was prepared from mouse cell lines
(L929, JLS-V9, EL4, RL1, YAC-1, BCL1-B20, P815, P388, RAW264.7, and M1). B, tissue cDNA (CLONTECH) was used after normalizing the
relative amounts according to the levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA. C, TG-PEC were analyzed for the binding
of mAbs LOM-14 and LOM-8.7. The cells highly or poorly reactive with mAb LOM-8.7 were separated and tested for mAb LOM-14 binding by flow
cytometry. cDNA was prepared from the sorted cells, and RT-PCR analysis was performed. The PCR products were then separated on 1% agarose
gels, stained with ethidium bromide, and visualized with the image analyzer. The ratios of band intensity of PCR products were measured. The
panels represent a typical result of two separate experiments including cell fractionations. The results of these two separate experiments were
almost identical.
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on RNA isolated from 13 different normal mouse tissues and
embryos (Fig. 4B). These genes were expressed almost
throughout the body, and the apparent relative intensities
among different organs were similar between mMgl1 and
mMgl2. To assess whether the expression levels of these
genes correspond at single cell levels, TG-PEC were sorted for
the binding of mAb LOM-8.7, an mAb specific for mMGL1,
and then reacted with mAb LOM-14 reactive with both
mMGL1 and mMGL2. As shown in Fig. 4C, cells strongly
reactive with mAb LOM-8.7 were also reactive with mAb
LOM-14. The ratios of expressed mRNAs corresponding to
mMgl1 and mMgl2 shown by RT-PCR analysis were almost
identical when unsorted mAb LOM-8.7-positive and mAb
LOM-8.7-negative cells were compared. These results indi-
cate that the mMgl1-positive cells also express the mMgl2
mRNA.
mMGL2-positive Cells in Tissue Sections from Mgl1/
Mice—Frozen sections of skins from Mgl1/ mice were stained
with mAb LOM-8.7 and mAb LOM-14 (Fig. 5). The results
revealed that Mgl1/ mice expressed epitopes reactive with
mAb LOM-14 at lower levels than Mgl1/ mice but not with
mAb LOM-8.7. These epitopes are likely to represent mMGL2.
The subcellular localization of the mAb LOM-14 staining in
Mgl1/ mice did not appear to be distinct from that of mAb
LOM-8.7 staining in Mgl1/ mice.
Carbohydrate Specificity of mMGL2—A variety of biotin-
labeled soluble polyacrylamides with mono- or oligosaccharides
were applied to determine the carbohydrate specificity of
mMGL1 and mMGL2 (Fig. 6). The carbohydrates tested are
listed in the figure. The recombinant form of mMGL1 had the
highest affinity with Lex residues among all carbohydrate-
modified polyacrylamides tested. mMGL2 showed a very low
affinity with LeX but showed the highest affinity with -linked
GalNAc residues (Fig. 6). The bindings were inhibited with 5
mM EDTA (data not shown).
pH-dependent Binding of Ligands to mMGL—Enzyme-
linked immunosorbent assays were performed under various
pH conditions to determine the binding of soluble polyacryl-
amides with LeX residues or -GalNAc residues to immobi-
lized recombinant mMGL1 or mMGL2, respectively. Under a
Ca2 concentration similar to that found in extracellular
fluids (0.905 mM), the binding decreased when pH was low-
ered from extracellular (pH 7.3) to endosomal (pH 5.4). The
profiles of the pH-dependent binding were similar to that
observed with intact hepatic asialoglycoprotein receptors
(31). The pH value of a half-maximal ligand binding, desig-
nated as pHB, was 5.5 for MGL1 and 5.7 for MGL2 (Fig. 7).
DISCUSSION
In the present study, we found a novel MØ C-type lectin,
mMGL2, and characterized its genomic structure, expression
patterns, and carbohydrate specificity. The Mgl2 gene spans
7136 bp and consists of 10 exons, which is a similar genomic
organization to that of the Mgl gene now renamed the Mgl1
gene. We reported that the Mgl1 gene linked to Trp53 and is
located 1.8  1.2 cM distal to D11Mit5 and 1.8  1.2 cM
proximal to Htt on mouse chromosome 11. Using a panel of
DNA samples from two parental mice, C3H/HeJ-gld and (C3H/
HeJ-gld  Mus spretus) F1 were digested with various restric-
tion endonucleases and hybridized with a mMGL1 cDNA probe
to determine the restriction fragment length polymorphism
and to allow haplotype analyses (29). The hepatic asialoglyco-
protein receptor genes (Asgr1 and Asgr2) were also known to be
linked to Trp53 (32). We found BAC clones, which included
these two C-type lectins. These results indicate that the highly
homologous Mgl2 gene is linked within about 50 kb. Their
homology and close genomic localization indicate that the orig-
inal gene was duplicated recently. The human MGL (HML-2)
gene was mapped in chromosome 17p and linked to ASGR1 and
ASGR2. These results show that there is a cluster of type 2
C-type lectin genes on mouse chromosome 11 and on human
17p12–13. Likewise, the natural killer gene complex resided on
mouse chromosome 6 and on human 12p (33, 34).
Although there was a high degree of sequence homology
between mMGL1 and mMGL2, the sequences corresponding to
cytoplasmic and CRD showed differences, suggesting that cy-
toplasmic tail associations and the carbohydrate recognitions
are unique between mMGL1 and mMGL2. We showed that
recombinant mMGL1 bound soluble polyacrylamides contain-
ing Lex oligosaccharides. mMGL2 had affinity with polyacryl-
amides containing - or -GalNAc. It has been believed that
C-type lectins contain a peptide segment that corresponds to
the carbohydrate binding specificity within the CRD and that
the sequence in Gal and GalNAc-binding lectins, such as AS-
GRs, is QPD. In contrast, the sequence in mannose-, fucose-,
and GlcNAc specific lectins, such as serum mannose-binding
proteins, was EPN. The sequence in both mMGL1 and -2 was
QPD. However, it was obvious from our results that their fine
specificities depended on other amino acids in the CRD (Figs. 6
and 8). Some of the amino acid residues important in the
FIG. 5. Distribution of cells express-
ing mMGL1 and mMGL2 in skins. Fro-
zen sections of skins from Mgl1/ and
Mgl1/ mice were stained with mAb
LOM-8.7 (specific for mMGL1) and mAb















carbohydrate recognitions were conserved in mMGL1,
mMGL2, hMGL, RHL-1 and -2, mASGR-1, and hASGR-1. Crys-
tallographic determination of the structure of human ASGR-1
revealed amino acid residues important in sugar binding (35).
Furthermore, rat hepatic asialoglycoprotein receptor was sub-
jected to site-directed mutation. As a result, the pH dependence
of ligand binding was shown to be mediated by His-256, Asp-
266, and Arg-270 (36). Because these residues are also con-
served in mMGL1 and -2, they should also be responsible for
their pH dependence (Fig. 8). Amino acid residues responsible
for the differential carbohydrate specificity between mMGL1
and -2 and other members of the C-type lectin family and the
phylogeny of these lectins (Fig. 8) are yet to be elucidated.
There is a possibility that mMGL1 and -2 form heterooli-
gomers. These lectins are known to form trimeric structures
through the interactions of the neck domain in a similar man-
ner to that of ASGRs. ASGRs are abundantly expressed on the
sinusoidal surface of hepatic parenchymal cells (37, 38). Its
primary role is the removal and degradation of desialylated
glycoproteins from circulation. High affinity binding requires
the receptor to be assembled as a heterooligomer consisting of
two highly homologous subunits, termed hepatic lectin 1 and 2
(39). Experiments with recombinant rat hepatic lectins sug-
gested that the binding properties of the major subunit
(RHL-1) and the minor subunit (RHL-2/-3) were optimized for
different ligands (40). In the case of mMGL1 and -2, the recom-
binant form corresponding to each one showed affinity with
different carbohydrates, indicating that heterooligomer forma-
tion was not required for their carbohydrate recognition. How-
ever, these lectins were likely to be expressed on the same cells
at the single cell level and cooperatively functioned to recognize
and uptake extracellular molecules.
mMGL1-positive cells are abundant in connective tissues
throughout the body (19). mMGL1 was shown to be expressed
on the surfaces of bone marrow-derived immature dendritic
cells (21). hMGL is also shown to be expressed on monocyte-
derived immature dendritic cells and monocyte-derived imma-
ture MØs in humans (41). We have shown that mMGL1-posi-
tive cells migrate from dermis to regional lymph nodes during
the sensitization phase of contact hypersensitivity (42). The
FIG. 6. Carbohydrate specificity of
recombinant mMGL1 and mMGL2.
Binding of biotin-labeled soluble poly-
acrylamides containing mono- or oligosac-
charides to immobilized recombinant
mMGL1 (A and C) and mMGL2 (B and D).
Amounts of bound polymers incubated at
various concentrations were quantified us-
ing HRP-conjugated streptavidin. ABTS
was used as a substrate, and absorbance at
405 nm was measured on a microplate
reader. The panels represent a typical re-
sult of three separate determinations,
which showed almost identical results.
Each assay was performed in duplicate,
and the mean value is shown.
FIG. 7. Effects of pH on binding of recombinant mMGL1 and
mMGL2. The binding of biotin-labeled soluble polyacrylamides (0.22
g/ml Lex polyacrylamide or 0.67 g/l -GalNAc polyacrylamide) to
the immobilized recombinant mMGL1 (A) or mMGL2 (B) was deter-
mined under varied pH conditions. The assays were performed in the
presence of 0.905 mM CaCl2. The values obtained in different buffers (25
mM sodium acetate buffer for pH 4.5–6.0, 25 mM MES buffer for pH
6.0–7.0, 25 mM Tris-HCl buffer for pH 7.0–8.0). The panels represent a
typical result of two separate determinations, which showed almost
identical results. The values represent means of duplicate
determinations.
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FIG. 8. Comparison of the amino acid sequences of the CRD of C-type lectins. A, multialignment of the CRD sequences of C-type lectins.
B, evolutionary tree of sequence of CRD of C-type lectins. Abbreviations used in this figure are: MHL, mouse hepatic lectin; rKCR, rat Kupffer cell














migration was initiated by cytokine-mediated release of
mMGL1-positive cells from dermis (42–44). The cells homed to
the boundary of the T-cell area in the regional lymph nodes,
and the prevention of migration seemed to interfere with sen-
sitization. Involvement of coordinated functions of mMGL1 and
-2 in such pathogenic processes should be the most important
subject of future investigations.
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